GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

GenScript Biotech reported first-half 2026 revenue of $404.2 million, up 27.3% year-over-year, with adjusted net profit surging 203.3% to $62.5 million. The Hong Kong-listed company's AI-enabled drug discovery business doubled compared to the same period last year, driven by demand from artificial intelligence-focused biotechnology and pharmaceutical companies. Gene-to-Protein, which accounts for 66% of GenScript Life Science Group revenue, remained the primary growth engine as clients increasingly seek experimental validation and development services for AI-discovered drug candidates.